PL3458067T3 - Leczenie chorób neurologicznych - Google Patents

Leczenie chorób neurologicznych

Info

Publication number
PL3458067T3
PL3458067T3 PL17725862T PL17725862T PL3458067T3 PL 3458067 T3 PL3458067 T3 PL 3458067T3 PL 17725862 T PL17725862 T PL 17725862T PL 17725862 T PL17725862 T PL 17725862T PL 3458067 T3 PL3458067 T3 PL 3458067T3
Authority
PL
Poland
Prior art keywords
treatment
neurological diseases
neurological
diseases
Prior art date
Application number
PL17725862T
Other languages
English (en)
Inventor
Denise RAGEOT
Paul Hebeisen
Florent Beaufils
Doriano Fabbro
Petra HILLMANN-WULLNER
Hoa Huu Phuc NGUYEN
Wolfgang Löscher
Claudia BRANDT
Alexander Markus Sele
Original Assignee
Torqur Ag
Universität Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torqur Ag, Universität Basel filed Critical Torqur Ag
Publication of PL3458067T3 publication Critical patent/PL3458067T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL17725862T 2016-05-18 2017-05-17 Leczenie chorób neurologicznych PL3458067T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16170107 2016-05-18
EP17725862.1A EP3458067B1 (en) 2016-05-18 2017-05-17 Treatment of neurological disorders
PCT/EP2017/025136 WO2017198346A1 (en) 2016-05-18 2017-05-17 Treatment of neurological disorders

Publications (1)

Publication Number Publication Date
PL3458067T3 true PL3458067T3 (pl) 2021-12-13

Family

ID=56024138

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17725862T PL3458067T3 (pl) 2016-05-18 2017-05-17 Leczenie chorób neurologicznych

Country Status (25)

Country Link
US (3) US20190284178A1 (pl)
EP (1) EP3458067B1 (pl)
JP (1) JP6991158B2 (pl)
KR (1) KR102472461B1 (pl)
CN (1) CN109475560B (pl)
AU (1) AU2017265383B2 (pl)
CA (1) CA3022753C (pl)
CY (1) CY1124051T1 (pl)
DK (1) DK3458067T3 (pl)
ES (1) ES2863250T3 (pl)
HR (1) HRP20210477T1 (pl)
HU (1) HUE053494T2 (pl)
IL (1) IL263080B (pl)
LT (1) LT3458067T (pl)
MX (1) MX2018014168A (pl)
PL (1) PL3458067T3 (pl)
PT (1) PT3458067T (pl)
RS (1) RS61655B1 (pl)
RU (1) RU2765868C2 (pl)
SG (1) SG11201809792TA (pl)
SI (1) SI3458067T1 (pl)
SM (1) SMT202100177T1 (pl)
TW (1) TWI753912B (pl)
WO (1) WO2017198346A1 (pl)
ZA (1) ZA201807393B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3458067T (lt) * 2016-05-18 2021-04-26 Torqur Ag Neurologinių sutrikimų gydymas
KR102483630B1 (ko) 2016-05-18 2023-01-02 토르쿠르 아게 피부 병변의 치료
BR112020009855A8 (pt) 2017-11-23 2023-01-10 Piqur Therapeutics Ag Tratamento de distúrbios de pele
MX2023011865A (es) * 2021-04-09 2024-01-08 Univ Basel Derivados de triazina como inhibidores de pi3k covalentes reversibles e irreversibles.
CN117396470A (zh) * 2021-04-09 2024-01-12 巴塞尔大学 作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060103A1 (es) 2006-02-09 2008-05-28 Alba Therapeutics Corp Formulaciones para un efector de uniones apretadas
PL2041139T3 (pl) * 2006-04-26 2012-05-31 Hoffmann La Roche Związki farmaceutyczne
AU2007282535B9 (en) * 2006-08-08 2013-06-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as PI3K inhibitor and use thereof
CA2675558A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
AU2014331049B2 (en) 2013-10-04 2018-03-29 Torqur Ag Conformationally restricted PI3K and mTOR inhibitors
MA40933A (fr) * 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
LT3458067T (lt) * 2016-05-18 2021-04-26 Torqur Ag Neurologinių sutrikimų gydymas
KR102483630B1 (ko) * 2016-05-18 2023-01-02 토르쿠르 아게 피부 병변의 치료
EP3458035B1 (en) 2016-05-18 2026-08-19 Torqur AG Bimiralisib and derivatives thereof for use in the treatment of actinic keratosis

Also Published As

Publication number Publication date
RU2765868C2 (ru) 2022-02-04
WO2017198346A1 (en) 2017-11-23
RU2018140013A3 (pl) 2020-07-09
US20240343718A1 (en) 2024-10-17
AU2017265383A1 (en) 2018-12-13
CA3022753A1 (en) 2017-11-23
AU2017265383B2 (en) 2022-07-28
US11878972B2 (en) 2024-01-23
EP3458067B1 (en) 2020-12-30
CN109475560B (zh) 2023-05-02
CN109475560A (zh) 2019-03-15
MX2018014168A (es) 2019-04-29
SMT202100177T1 (it) 2021-05-07
CA3022753C (en) 2024-09-24
TWI753912B (zh) 2022-02-01
CY1124051T1 (el) 2022-05-27
HRP20210477T1 (hr) 2021-05-14
BR112018073579A8 (pt) 2023-01-10
US20220135551A1 (en) 2022-05-05
LT3458067T (lt) 2021-04-26
RS61655B1 (sr) 2021-04-29
SG11201809792TA (en) 2018-12-28
RU2018140013A (ru) 2020-06-18
JP6991158B2 (ja) 2022-02-10
KR20190008294A (ko) 2019-01-23
IL263080B (en) 2022-02-01
US20190284178A1 (en) 2019-09-19
BR112018073579A2 (pt) 2019-03-19
NZ748601A (en) 2024-12-20
KR102472461B1 (ko) 2022-11-30
PT3458067T (pt) 2021-04-07
HUE053494T2 (hu) 2021-06-28
ZA201807393B (en) 2023-10-25
ES2863250T3 (es) 2021-10-11
SI3458067T1 (sl) 2021-07-30
EP3458067A1 (en) 2019-03-27
IL263080A (en) 2018-12-31
JP2019519507A (ja) 2019-07-11
DK3458067T3 (da) 2021-04-06
TW201808944A (zh) 2018-03-16

Similar Documents

Publication Publication Date Title
HUE060711T2 (hu) Makrociklusos vegyületek betegségek kezelésére
PL3416631T3 (pl) Środki terapeutyczne do leczenia chorób neurodegeneracyjnych
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
ZA201903003B (en) Treatment of neurological diseases
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
PL3169328T3 (pl) Pochodne chinoliny do leczenia chorób zapalnych
EP3273955A4 (en) TREATMENT OF RESPIRATORY DISEASES
IL257764B (en) Methods for treatment of diseases
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
MA42930A (fr) Traitement de maladies neurodégénératives
HUE059387T2 (hu) Parkinson-kór kezelése
IL270900A (en) Treatment of cutaneous disorders
GB201412578D0 (en) Treatment of neurological diseases
IL263080B (en) Treatment of neurological disorders
IL264603A (en) Reelin compositions for treatment of neurological disorders
IL262801A (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme
GB201714307D0 (en) Treatment of neurodegenerative diseases
IL259381B (en) Mirabegron for the treatment of retinal diseases
PL3302499T3 (pl) Leczenie chorób mitochondrialnych
GB201714303D0 (en) Treatment of neurodegenerative diseases
IL263837A (en) Treatment of ocular disease
GB201714311D0 (en) Treatment of neurodegenerative diseases
GB201706662D0 (en) Treatment of neurological diseases